Skip to content

Ontario Data: Vaccination Linked to Higher COVID Rates

Day 3 · 0:29:04 · Deanna McLeod · Dean Allison

  • 📈 FOIA population data show unvaccinated cases falling after Omicron while one-to-two-dose and boosted groups carried the highest case rates.
  • 💉 Each booster rollout coincided with elevated infection risk in that cohort—the opposite of public messaging.
  • 🔄 Regulatory changes allow new mRNA codes inside approved lipid nanoparticles with no fresh clinical trials or cumulative toxicity studies.

Provincial administrative data reverse the claimed effectiveness narrative.

← Pfizer Trial Data: Risks Outweigh Benefits | 14-Day Status Delay Masks Early Injuries and Infections →

Transcript

Deanna McLeod · 0:29:04

And so what we have here is the data from Ontario, Canada. This is basically, uh, data from a FOIA request where we asked, um, them to give the data for COVID cases by vaccination status, and it's a complicated graph, but I'm just going to walk you through it. So if you did not get vaccinated, then you would follow the blue line. The blue line moves along, you have a couple peaks before October.

Dean Allison · 0:29:34

Can I just stop you? So it says unexposed, but it could say unvaccinated.

Deanna McLeod · 0:29:39

That's right, in the figure. So that's unexposed to the mRNA product. We did a paper, we didn't actually want to call it a vaccine because technically speaking it isn't like a traditional vaccine, so thank you for highlighting that. So initially, if you did not get vaccinated, basically you have a couple peaks, and then when Omicron arrived, which is the, the date at January 2022, when you see that big peak, there's a little bit of a peak, and then you'll see that there is no more cases afterwards. It just peters off completely. If you actually look at the vaccinated, so that's the 2 doses, which is the orange line, you see that when they began rollout, there was an immediate spike in COVID cases among the vaccinated, the ones that got 1 to 2 doses. Then it petered down a little bit, and then with the arrival of Omicron, you can see that the highest level of case rates, the number of cases per population per 100,000, is in the vaccinated, those 1 to 2 doses, those who have received a 1 to 2 dose. And while they were rolling out the, um, the, the booster is when Omicron happens.

Deanna McLeod · 0:30:47

So we have Omicron and they're rolling out a booster, and if you look at that, they also peak. And then they're from Omicron onward, the highest rates are in the boosted. So what this data tells us is that vaccination increases your risk of COVID infection. Uh, it also tells us that—.

Dean Allison · 0:31:09

I just have to stop you so people hear that again. So this is using Province of Ontario data. This is the province's data on rates of COVID and then you've just said, so from Omicron on, that actually it appears that the vaccines— a major side effect is COVID, that you're more likely to get COVID when you're vaccinated.

Deanna McLeod · 0:31:32

So what we're looking at is population data, so I can't actually assert a causal link between this, but what I can say is that following the vaccination at a population level in Ontario, people who were vaccinated had an increased risk of getting COVID versus people who were unvaccinated. And again, this data was readily available to officials if they wanted to look at it. This is Ontario data. Pulling administrative data and analyzing it is standard practice. But it does look like even whenever you added the booster, that, you know, with the addition, and that when, you know, when we say boosted, it's, you know, 3 doses or more because they kept boosting people, that those— that group has the highest risk of COVID following the rollout of the booster. So it seems to me that once you roll it out, then you actually have increased risk in that particular population. So this would be the opposite of what we were told.

Dean Allison · 0:32:34

And I'll just, just ask, so I mean, because we're— this, your chart goes from up till, looks like, just shy of January 2024, but it looks like around February of '22 onwards, those that were boosted were, on a population level, they were, they were more likely to get COVID because they were getting COVID more than the unvaccinated. Now we're still boosting. I don't know what shot we're up to, but I know people that are still getting, getting boosted and nobody is telling them that with each booster, because it continues, doesn't it, that with each booster you are more likely to get COVID.

Deanna McLeod · 0:33:14

Interestingly enough, there was a regulatory change through COVID that's still in play. And basically for the mRNA products, what they do is they approve the lipid nanoparticle part, which is the fat capsule that it's in, and then basically they can change the code, the mRNA code within that without doing any further clinical evaluation. So basically we don't even do biomarkers. So each of these boosters that we're recommending right now, A, we haven't actually ever analyzed the cumulative toxicity. There's no study that actually looks at that. And then secondly, they're not even actually doing any clinical evidence, any clinical trials, or evaluating whatsoever any of the products that are now being put out. So it's, it's, it's an interesting— there's definitely not enough clinical evidence to support that recommendation to continue to boost.

Dean Allison · 0:34:08

And I'm just gonna— I just realized we're under a tight time schedule, so I better stop interrupting you. Yeah. And get you proceeding.